Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 1.00 |
| ▸ | NPC1 | O15118 | 10/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.73 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.73 |
| ▸ | MLYCD | O95822 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2332195 | 0.93 | RAB9A (0.88) | RAB9ANPC1HDAC2HDAC8HDAC6 | |
| SCHEMBL28905659 | 0.90 | NPC1 (1.00) | RAB9ANPC1HDAC2HDAC8HDAC6 | |
| SCHEMBL17372505 | 0.88 | NPC1 (0.79) | RAB9ANPC1HDAC2HDAC8HDAC6 | |
| SCHEMBL751214 | 0.88 | HDAC2 (0.80) | RAB9ANPC1HDAC2HDAC8HDAC6 | |
| SCHEMBL22776280 | 0.87 | NPC1 (0.75) | RAB9ANPC1HDAC2HDAC8HDAC6 | |
| SCHEMBL6841899 | 0.86 | HDAC2 (0.78) | RAB9ANPC1HDAC2HDAC8HDAC6 | |
| SCHEMBL7282271 | 0.86 | HDAC2 (0.78) | RAB9ANPC1HDAC2HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL28193721 | 0.86 | HDAC2 (0.77) | RAB9ANPC1HDAC2HDAC8HDAC6 | |
| SCHEMBL22777679 | 0.85 | NPC1 (0.74) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6571020 | 0.85 | HDAC2 (1.00) | RAB9ANPC1HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113950477-B | Granulin precursor modulators and methods of use thereof | 阿库达医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-3724188-B1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2022-12-29 | — | — | US | disclosed |
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2022-12-29 | — | — | US | disclosed |
| EP-4048677-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20220251084-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-11 | — | — | US | disclosed |
| EP-3983401-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-113950477-A | Modulators of progranulin and methods of use thereof | 阿库达医疗公司 | 2022-01-18 | — | — | CN | disclosed |
| US-20210163471-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2021-06-03 | — | — | US | disclosed |
| WO-2021081272-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2021-04-29 | — | — | WO | disclosed |
| US-9944750-B2 | Polyethylene glycol substituted acyl borates | ETH ZURICH (CH) | 2018-04-17 | — | — | US | disclosed |
| EP-3092263-B1 | POLYETHYLENE GLYCOL SUBSTITUTED ACYL BORATES | ETH ZUERICH (CH) | 2018-02-21 | — | — | EP | disclosed |
| US-20170022321-A1 | POLYETHYLENE GLYCOL SUBSTITUTED ACYL BORATES | ETH ZURICH (CH) | 2017-01-26 | — | — | US | disclosed |
| US-20170022321-A1 | POLYETHYLENE GLYCOL SUBSTITUTED ACYL BORATES | ETH ZURICH (CH) | 2017-01-26 | — | — | US | disclosed |
| WO-2015104374-A1 | POLYETHYLENE GLYCOL SUBSTITUTED ACYL BORATES | ETH ZURICH (CH) | 2015-07-16 | — | — | WO | disclosed |
| US-20100292269-A1 | BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-11-18 | — | — | US | disclosed |
| EP-0901488-B1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2002-11-06 | — | — | EP | disclosed |
| EP-0901488-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-17 | — | — | EP | disclosed |
| US-5866583-A | Substituted 2,4-diaminopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1997043277-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251084-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PRNP, PSEN2 | RAB9A 3045/4885NPC1 381/4885HDAC2 2859/4885 |
| US-20210163471-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PRNP, PSEN1 | RAB9A 2951/4885NPC1 325/4885HDAC2 2844/4885 |
| US-20100292269-A1 | BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC3, BIRC2 | RAB9A 949/4885NPC1 3616/4885HDAC2 4221/4885 |
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PSEN1, PSEN2 | RAB9A 3103/4885NPC1 156/4885HDAC2 3679/4885 |
| US-20170022321-A1 | POLYETHYLENE GLYCOL SUBSTITUTED ACYL BORATES | BRS3, FFAR3, LPAR3 | RAB9A 3398/4885NPC1 1589/4885HDAC2 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.